Aligos Therapeutics, Inc. (ALGS) — 10-Q Filings

10-Q Filings (6)

• Aligos' Q3 Loss Widens to $31.5M Amid Rising R&D, Warrants Boost YTD — Nov 6, 2025 Risk: high
  Aligos Therapeutics, Inc. reported a net loss of $31.537 million for the three months ended September 30, 2025, a significant increase from the $19.259 million
• Aligos Reports Q2 Net Loss of $18.5M, Advances Pipeline — Aug 6, 2025 Risk: high
  Aligos Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company incurred a
• Aligos Therapeutics Q1 2025 10-Q: Funding, Licensing, R&D — May 6, 2025 Risk: medium
  Aligos Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial status, including details on common stock a
• Aligos Therapeutics Files Q3 2024 10-Q — Nov 6, 2024 Risk: medium
  Aligos Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company's fiscal year ends on December 31st. Key dates mentioned include
• Aligos Therapeutics Q2 2024 10-Q Filed — Aug 6, 2024 Risk: medium
  Aligos Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial condition and results of operations, includi
• Aligos Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk: medium
  Aligos Therapeutics, Inc. (ALGS) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Aligos Therapeutics, Inc. filed a 10-Q report for the period endin

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX